Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
NEWARK, Calif., Nov. 13, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will provide a corporate overview at the 29th Annual Piper Jaffray Healthcare Conference, the Evercore/ISI 2017 Biopharma Catalyst/Deep Dive Conference, and the Global Mizuho Investor Conference.
| 29th Annual Piper Jaffray Healthcare Conference | ||||
| Date: | Wednesday, November 29 | |||
| Time: | 12:00pm Eastern time | |||
| Location: | Lotte New York Palace Hotel | |||
| Webcast: | http://ir.cymabay.com/events | |||
| Evercore/ISI 2017 Biopharma Catalyst/Deep Dive Conference | |||||
| Date: | Thursday, November 30 | ||||
| Time: | 12:05pm Eastern Time | ||||
| Location: | Boston Harbor Hotel | ||||
| Webcast: | http://ir.cymabay.com/events | ||||
| Global Mizuho Investor Conference | |||
| Date: | Tuesday, December 5 | ||
| Time: | One-on-One Format | ||
| Location: | Lotte New York Palace Hotel | ||
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent and selective agonist of PPARδ, a nuclear receptor that regulates genes involved in bile acid/sterol, lipid and glucose metabolism and inflammation. Seladelpar is currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH. Arhalofenate is a potential urate-lowering anti-flare therapy that has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
For additional information about CymaBay visit www.cymabay.com.
Contact:
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
[email protected]
